SecBot SecBot
8-K ·Filed Nov 12, 2026

TWST

Twist Bioscience Corp
BULLISH
Impact 6/10
Horizonmonths Processed4d 14h ago SEC0001581280-26-000053
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

Monitor Q1 FY2027 results for continued sequential growth and margin expansion. The company's ability to sustain adjusted EBITDA profitability and execute on its $75M capex plan will be key. AI drug discovery revenue assumption of $100M in FY2027 guidance is a new growth vector to track.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$114.22
T+0 close · Nov 12, 2026 · via day close
Latest settled
−2.29%
T+1 · $111.60
Vs SPY
−1.93%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $114.22entry
  2. T+1 · 4d ago −2.29%α −1.93% · $111.60
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Twist Bioscience reported fiscal Q4 2026 revenue of $126.6M (+28% YoY), above the $123.6M consensus, and achieved positive adjusted EBITDA of $2.2M for the first time. The company guided FY2027 revenue to $550M-$560M (21% YoY growth at the midpoint) and expects continued adjusted EBITDA profitability. Net loss narrowed to $20.6M from $27.1M a year ago.

Key Financial Metrics

EPS
−$0.32
est −$0.20 · -60.0%
Revenue
$126.6M
est $123.6M · +2.5% · +27.9% YoY
Rating
in line
Guidance
$550M-$560M
initiated
Gross Margin
53.1%

Key Facts

  • Q4 FY2026 revenue $126.6M, up 28% YoY from $99.0M, above consensus of $123.6M
  • Full year FY2026 revenue $459.4M, up 22% YoY from $376.6M
  • Q4 adjusted EBITDA positive at $2.2M vs $(7.8M) a year ago, achieving breakeven milestone
  • FY2027 revenue guidance $550M-$560M, 21% YoY growth at midpoint
  • Q1 FY2027 revenue guidance $130M-$132M, 26% YoY growth at midpoint
  • Gross margin expanded to 53.1% in Q4 from 51.3% a year ago
  • Cash position strengthened to ~$582M after raising ~$425M in equity offering
  • DSPS segment grew 33% YoY to $61.0M; NGS segment grew 24% YoY to $65.7M in Q4

Financial Impact

Revenue beat consensus by ~$3M (2.4%); positive adjusted EBITDA milestone achieved; FY2027 guidance implies 21% revenue growth

revenuegross marginadjusted EBITDAcash position

Segment Breakdown

SegmentRevenueGrowth
DNA Synthesis and Protein Solutions (DSPS)$61.0M+33.0%
NGS Applications (NGS)$65.7M+24.0%

Risk Factors

  • Net loss widened to $130.2M for FY2026 from $77.7M in FY2025, driven by higher SG&A expenses
  • Selling, general and administrative expenses grew 22% YoY to $301.2M, outpacing revenue growth
  • Guidance assumes $100M in AI drug discovery revenue, a new and unproven segment
  • Capital expenditures of ~$75M planned for FY2027 may pressure cash flow

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
74% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001581280-26-000053
Document: twist-20261112.htm0001581280-26-000053
Document: 0001581280-26-000053-index-headers.html0001581280-26-000053
Document: 0001581280-26-000053-index.html0001581280-26-000053
Document: 0001581280-26-000053.txt0001581280-26-000053
8-K Data (Synthetic)0001581280-26-000053

Track record

47 reports on TWST

Performance horizon

8 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +55.24% at T+60 after the Aug 3, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $105.03 Now $105.04 +0.01% settles Dec 15
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $105.16 Now $105.04 −0.11% settles Dec 15
  3. Nov 16, 2026today 144 Neutral 2/10 Entry $104.98 Now $105.04 +0.06% settles Dec 15
  4. Nov 16, 2026today 144 Neutral 2/10 Entry $105.61 Now $105.04 −0.54% settles Dec 15
  5. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $104.03 Now $105.04 +0.98% settles Dec 15
  6. Nov 12, 20264d ago 8-K Bullish 6/10 Viewing Entry $114.22 Now $105.04 −8.04% settles Dec 11
  7. Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $114.22 Now $105.04 −8.04% settles Dec 11
  8. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $132.13 Now $105.04 −20.50% settles Dec 9
  9. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $120.79 Now $105.04 −13.04% settles Dec 7
  10. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $120.61 Now $105.04 −12.91% settles Dec 4
Showing 10 of 47

US Market Status

Market Closed · Opens Wed (11h 47m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026